Chemically linked Fab
Fab' fragments linked with a thioether, resulting in a F(ab')2. The molecule is bound to a tumour cell via the tumour antigen CD30 and to a macrophage via an Fc receptor
.Two chemically linked fragments antigen-binding form an artificial
immune cell, for example an Fc receptor on a macrophage. In this way, tumour cells are attached to immune cells, which destroy them.[3]
In the late 1990s and early 2000s, clinical trials with chemically linked Fabs were conducted for the treatment of various types of cancer. Early results were promising,[3][4] but the concept was dropped because of high production costs.[5]
Bi-specific T-cell engagers employ a similar mechanism of action while being cheaper.
References
- PMID 6239899.
- PMID 2958547.
- ^ PMID 12384405.
- PMID 9650561.
- ^ Kellner, C (2008). Entwicklung und Charakterisierung bispezifischer Antikörper-Derivate zur Immuntherapie CD19-positiver Leukämien und Lymphome [Development and characterisation of bispecific antibody derivatives for the immunotherapy of CD19-positive leukaemia and lymphoma] (Thesis) (in German and English). Erlangen-Nürnberg: Friedrich-Alexander-Universität.
Engineered monoclonal antibodies and antibody mimetics | ||
|---|---|---|
| Whole antibody |  | |
| Fab fragment | ||
| Variable fragment | ||
| Smaller units | ||
| Intracellular | ||
| Antibody mimetics | ||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |